High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
Flora Zagouri(National and Kapodistrian University of Athens), Martin Filipits(University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Aris Giannos(National and Kapodistrian University of Athens), Fabian Rössler(Comprehensive Cancer Center Vienna), Irene Papaspyrou(National and Kapodistrian University of Athens), Constantine Dimitrakakis(National Institutes of Health), Anita Brandstetter(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), C.A. Papadimitriou, Alexandra Tsigginou(National and Kapodistrian University of Athens)
Cited by 98
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303